Platelet alpha 2-adrenoceptor modifications induced by long-term treatment with indapamide in essential hypertension. 1988

R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
Istituto di Patologia Medica and Pharmacology, Trieste's University, Italy.

The effect of long-term treatment with indapamide in platelet alpha 2-adrenoceptors has been evaluated in 10 patients with essential hypertension, in a double-blind, cross-over study with placebo. After three months of therapy, indapamide significantly reduced mean blood pressure (from 137 +/- 12 to 116 +/- 6 mm Hg, p less than 0.001), whereas heart rate did not change (from 72 +/- 8 to 73 +/- 7 beats/minute). At the same time, platelet alpha 2-adrenoceptor number increased (from 168.2 +/- 48.4 to 256.8 +/- 14.5 fmol/mg protein, p less than 0.02), whereas the dissociation constant did not change (from 3.79 +/- 2.9 to 4.97 +/- 4.48). The plasma norepinephrine level was significantly reduced after long-term treatment with indapamide (from 275 +/- 118 to 210 +/- 56 pg/ml, p less than 0.02). These results bring about an inhibition of norepinephrine release from sympathetic nerve endings with a likely secondary increase of the number of platelet alpha 2-adrenoceptors.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007190 Indapamide A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS. Metindamide,S-1520,SE-1520,S 1520,S1520,SE 1520,SE1520
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011942 Receptors, Adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation. Adrenergic alpha-Receptor,Adrenergic alpha-Receptors,Receptors, alpha-Adrenergic,alpha-Adrenergic Receptor,alpha-Adrenergic Receptors,Receptor, Adrenergic, alpha,Adrenergic alpha Receptor,Adrenergic alpha Receptors,Receptor, alpha-Adrenergic,Receptors, alpha Adrenergic,alpha Adrenergic Receptor,alpha Adrenergic Receptors,alpha-Receptor, Adrenergic,alpha-Receptors, Adrenergic
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic

Related Publications

R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
December 1982, Minerva cardioangiologica,
R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
May 1981, La Clinica terapeutica,
R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
September 1988, Kidney international. Supplement,
R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
January 1985, Hypertension (Dallas, Tex. : 1979),
R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
February 1999, British journal of clinical pharmacology,
R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
May 1991, Journal of clinical pharmacology,
R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
December 1981, Clinical science (London, England : 1979),
R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
January 1980, British journal of clinical pharmacology,
R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
January 1985, Journal of cardiovascular pharmacology,
R Carretta, and B Fabris, and F Fischetti, and S Muiesan, and M Bardelli, and C Melchior, and R Cesanelli, and A Pizzolitto, and T Giraldi, and P L Greco
July 1987, British journal of clinical pharmacology,
Copied contents to your clipboard!